A
Agilent Technologies, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Chemical and advanced materials revenue growth | 8% | Q2 FY2026 call | — |
| Diagnostics and clinical revenue growth | 11% | Q2 FY2026 call | — |
| operating margin non-GAAP | 26.4% | Q2 FY2026 call | — |
| operating margin sequential improvement non-GAAP | 180 | Q2 FY2026 call | — |
| operating margin year-over-year improvement non-GAAP | 130 | Q2 FY2026 call | — |
| Pharma revenue growth | 6% | Q2 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
A
this stock
Agilent Technologies, Inc.
|
$37.93B | -0.9% | +6.4% | 27.0 | 1.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$195.86B | -9.0% | +0.4% | 29.0 | 1.4% |
|
DHR
Danaher Corp /De/
|
$140.88B | -12.7% | +8.5% | 38.4 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.46B | -16.7% | +10.4% | 41.5 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.66B | +17.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| A | +2.8% | +2.0% | -7.1% | +1.1% | -0.9% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +1.4% | -2.0% | -16.1% | +0.0% | -11.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.